Cold-Chain Claims and Counterfeit Products

What FDA and WHO have said about counterfeit and falsified semaglutide, products arriving warm, and fake pharmacy labels, and why cold-chain and authenticity claims cannot be taken at face value.

Content last updated October 22, 2026. This page has not been medically reviewed.

First: if you already used a suspect product

Do not keep using a pen or vial that FDA or WHO has flagged, or one that arrived warm or damaged. If you feel unwell, seek medical care. In the US, call 911 in an emergency; US Poison Help is 1-800-222-1222 (see Poison Help by Country). WHO advises anyone who used an affected product, or had an unexpected reaction, to seek immediate medical advice. [1] Do not stop or change a prescribed medicine on your own; ask the prescriber or pharmacist.

Counterfeit, falsified and "cold chain": what the words mean

A counterfeit or falsified medicine misrepresents what it is or where it came from. FDA says counterfeit drugs claim to be authentic but could contain the wrong ingredients, too little, too much or no active ingredient, or other harmful ingredients. [2] The cold chain is the temperature-controlled path from manufacturer to patient. FDA says injectable GLP-1 drugs require refrigeration as stated in their package inserts. [2] A seller saying a product is "cold-shipped" is a marketing claim; it is not a regulator finding.

Evidence labels: evidence of harm (regulator-documented problems) and marketing claim.

Products that arrive warm

FDA says it has received complaints that certain compounded GLP-1 drugs arrived warm or with inadequate ice packs, and recommends that patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, as this can affect quality. [2] WHO likewise advises being wary of unusually low prices and injectable semaglutide stored outside the refrigerator. [5] Stability science is in Stability and Storage: Why Peptides Degrade.

Fake labels on compounded products

FDA is aware of fraudulent compounded semaglutide and tirzepatide with false label information. In some cases the compounding pharmacies named on the labels do not exist; in others the label names a licensed pharmacy that FDA's information shows did not compound the product. [2]

What this means in practice

Authenticity cannot be confirmed from a photo, a website or a seller's word. Regulators repeat the same guidance: obtain prescription medicines with a valid prescription from a state-licensed pharmacy. [4][2] See also Regulatory Warning Letters and Alerts and Mislabeling, Incorrect Strength and Degradation Products. Laws and alerts change and this is not legal advice. FDA and WHO findings here concern the products they name, not all peptides.

Frequently asked questions

Has counterfeit Ozempic been found in the US?

Yes. FDA has issued alerts in December 2023, April 2025 and December 2025 about counterfeit Ozempic in the US drug supply chain. [4]

Can a counterfeit pen have a real lot number?

FDA reported counterfeit product labeled with lot PAR1229, which is also an authentic lot number. [4]

What should I do if my injectable arrives warm?

FDA recommends not using any injectable GLP-1 drug that arrives warm or with insufficient refrigeration. [2] Contact the pharmacy or prescriber.

Does "cold-chain shipped" prove a product is genuine?

No. It describes handling, not identity. WHO and FDA both advise using licensed pharmacies. [3][2]

Where can problems be reported?

FDA encourages reporting adverse events or quality problems to its MedWatch program. [2]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

What regulators have documented for semaglutide

Source and date	What it reports
WHO Medical Product Alert N°2/2024	Three falsified batches of Ozempic detected in Brazil (October 2023), the UK (October 2023) and the US (December 2023), supplied in the regulated supply chain; the genuine manufacturer confirmed they were falsified [1]
WHO news release, 20 June 2024	WHO had seen increased reports of falsified semaglutide in all geographical regions; in other cases an undeclared active ingredient such as insulin may be present [3]
FDA alert, 12/21/2023	Thousands of counterfeit units seized; needles counterfeit, so sterility cannot be confirmed, which raises infection risk [4]
FDA alert, 4/14/2025	Several hundred counterfeit units seized; FDA and Novo Nordisk had no information yet on identity, quality or safety [4]
FDA alert, 12/5/2025	Dozens of counterfeit units in the legitimate US supply chain; the counterfeit carried a real lot number, so lot number alone did not identify it [4]

The 2025 case shows why a real-looking lot number is not proof. FDA described a label-position difference on that lot, and said testing of the seized product was underway. [4] We do not describe how to inspect a pen at home beyond the regulator's own alert, because those alerts apply to specific lots and change.

Warning signs FDA lists

FDA lists red flags for telehealth sellers: claims that a compounded drug is the same as an approved drug, prices that seem too good to be true, medicine that looks different from what was pictured or arrives in damaged packaging without instructions, no screening or prescription by a licensed doctor, no doctor available afterward, and spelling errors or wrong addresses on the label. [2] These are warning signs, not proof either way.

Illegal online sales and "research" vials

FDA says it monitors the internet and has issued warning letters about illegally marketed semaglutide and tirzepatide, which may be counterfeit or contain the wrong, too little, too much or no active ingredient. [2] FDA has also warned companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled "for research purposes" or "not for human consumption." [2] FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs. [2]

A 2026 case report described an 18-year-old with no medical history who developed euglycemic ketoacidosis after starting semaglutide bought online; the authors cite uncertainty about dosing and purity of unregulated online products as a possible contributor. This is one case and cannot show cause. [6]

References

World Health Organization, Medical Product Alert N°2/2024: Falsified OZEMPIC (semaglutide), 19 June 2024). Read 2026-10-22.
U.S. Food and Drug Administration, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026). Read 2026-10-22.
World Health Organization, WHO issues warning on falsified medicines used for diabetes treatment and weight loss, 20 June 2024. Read 2026-10-22.
U.S. Food and Drug Administration, FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain (updates 12/21/2023, 4/14/2025, 12/5/2025). Read 2026-10-22.
World Health Organization, Questions and answers on semaglutide injection products. Read 2026-10-22.
Euglycemic ketoacidosis following the use of counterfeit semaglutide for weight loss (case report), Cureus 2026. Read 2026-10-22 (abstract).

Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.